2-APQC |
رقم الكتالوجGC73817
One-Click Copy Product Info
|
2-APQC هو منشط SIRT3 مع قيمة Kd 2.756 ميكرومتر.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 500271-63-6
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
2-APQC is an orally active and selective agonist of Sirtuin-3 (SIRT3), with a KD value of 2.756μM[1]. 2-APQC upregulates the expression levels of AMPK/SIRT3 proteins, downregulates the expression levels of cellular aging and inflammation, and prevents ribosomal stress to alleviate kidney inflammation and senescence[2]. 2-APQC ameliorates acid-sensing ion channel 1a (ASIC1a)-mediated mitophagy levels, reduces mitochondrial superoxide release, and decreases the expression of PANoptosis-related proteins[3]. 2-APQC improves the migration ability of mouse dermal fibroblasts under high glucose conditions by increasing the protein levels of SIRT3 and SOD2, and decreasing the expression of acSOD2, COL1, and α-SMA[4]. 2-APQC has been used to mitigate endothelial ferroptosis and microvascular hyperpermeability[5].
In vitro, 2-APQC (10µM) treatment for 24 hours enhanced the thermal stability of SIRT3 in H9c2 cells and reduced the hypertrophy and fibrosis of cardiomyocytes induced by isoproterenol (ISO)[1]. Incubation with 10mM 2-APQC for 24 hours alleviated β-glycerophosphate-induced senescence of C2C12 cells, restored autophagy function, and decreased the expression levels of P53 and P62[6].
In vivo, 2-APQC treatment via a single intraperitoneal injection at a dose of 30mg/kg attenuated Lipopolysaccharide and Norepinephrine-induced cardiomyopathy, improved cardiac remodeling, and was accompanied by elevated heme oxygenase-1 expression and ferrous ion levels in mice 7 days later[7]. Intraperitoneal injection of 2-APQC (42mg/kg/day) for 30 days alleviated intervertebral disc degeneration induced by D-galactose (D-gal) in mice, maintained structural integrity, increased proteoglycan content, and restored mitochondrial homeostasis[8]. A single intraperitoneal injection of 2-APQC (20mg/kg) reduced the cerebral infarction volume in mice with cerebral Ischemia/reperfusion and attenuated neurological dysfunction within 7 days[9].
References:[1] Peng F, Liao M, Jin W, et al. 2-APQC, a small-molecule activator of Sirtuin-3 (SIRT3), alleviates myocardial hypertrophy and fibrosis by regulating mitochondrial homeostasis[J]. Signal Transduction and Targeted Therapy, 2024, 9(1): 133.
[2] Xie R, Liu M, Xu T, et al. Effects of Selenium Deficiency and the Environmental Pollutant Trimethylstannyl Chloride on Aging in Broiler Chickens Based on Adverse Outcome Pathways[J]. Journal of Agricultural and Food Chemistry, 2026, 74(1): 1602-1614.
[3] Zai Z, Qian X, Xu Y, et al. ASIC1a induces excessive mitophagy and PANoptosis of chondrocyte by the inhibition of SIRT3 mitochondrial translocation[J]. Theranostics, 2025, 15(18): 9623.
[4] Ge X, Ye Z, Qin H, et al. Thiomyristoyl Promotes Type 2 Diabetic Wound Healing and Inhibits Scarring via the PPARγ/Sirt3/SOD2 Axis[J]. Free Radical Biology and Medicine, 2026.
[5] Gao F, Li Z, Peng T, et al. SIRT3-mediated mitophagy by deacetylating ATP5F1A involved in the protective effects of SIGMAR1/Sigma-1 receptor against ferroptosis and microvascular hyperpermeability in lipopolysaccharide-induced acute lung injury[J]. Autophagy, 2026, 22(6): 1221-1235.
[6] Xu C, Xiong L, Chen J, et al. Sirtuin 3 modulation by high phosphates: a potential mechanism in muscle aging and sarcopenia[J]. American Journal of Translational Research, 2025, 17(6): 4187.
[7] Ma D, Fang W, Cai L, et al. Norepinephrine exacerbates LPS-induced cardiomyopathy via SIRT3/HO-1 axis-mediated ferroptosis[J]. Critical Care, 2025, 29(1): 354.
[8] Du Y, Lv Y, Liu X, et al. Activation of Sirt3 reprograms mitochondrial function to regenerate intervertebral disc degeneration[J]. Experimental Gerontology, 2026: 113228.
[9] Lei W, Dong Y, Zhuang H, et al. Astrocytic SIRT3 alleviates neuroinflammatory responses after cerebral ischemia/reperfusion by inhibiting the cGAS-STING pathway[J]. Inflammation, 2026, 49(1): 32.
| Cell experiment [1]: | |
|
Cell lines |
H9c2 cells |
|
Preparation Method |
H9c2 cells were cultured in DMEM medium, supplemented with 10% fetal bovine serum, 100U/ml penicillin, and 100μg/ml streptomycin at 37°C in an incubator with 5% CO2. In 96-well plates, H9c2 cells were plated in triplicate and subjected to 24h treatments with different concentrations of 2-APQC (0, 2.5, 5, and 10µM). After administering ISO to the cells for 48h, and cell viability was tested. |
|
Reaction Conditions |
0, 2.5, 5, and 10µM; 24h |
|
Applications |
2-APQC treatment markedly mitigated ISO-induced cell death in H9c2 cells. |
| Animal experiment [2]: | |
|
Animal models |
Male C57BL/6 J mice |
|
Preparation Method |
Male C57BL/6 J mice (8 weeks old) were housed in SPF conditions with an automatic 12h/12h light-dark cycle at a constant temperature (20-25°C). During the first month, mice in the D-gal and D-gal+2-APQC groups received daily intraperitoneal injections of D-gal (100mg/kg/day), while Control mice received equivalent volumes of sterile PBS. After 30 days, mice in the D-gal+2-APQC group additionally received intraperitoneal injections of 2-APQC (42mg/kg/day) dissolved in DMSO. Control and D-gal groups received equivalent volumes of DMSO. All treatments continued for a total duration of 60 days, after which mice were euthanized for tissue collection and analysis. |
|
Dosage form |
42mg/kg/day; 30 days; i.p. |
|
Applications |
2-APQC treatment ameliorated D-gal-induced intervertebral disc degeneration-associated pathological changes in mice, evidenced by restored mitochondrial function, reduced inflammation, and cellular senescence. |
| References: [1] Peng F, Liao M, Jin W, et al. 2-APQC, a small-molecule activator of Sirtuin-3 (SIRT3), alleviates myocardial hypertrophy and fibrosis by regulating mitochondrial homeostasis[J]. Signal Transduction and Targeted Therapy, 2024, 9(1): 133. [2] Du Y, Lv Y, Liu X, et al. Activation of Sirt3 reprograms mitochondrial function to regenerate intervertebral disc degeneration[J]. Experimental Gerontology, 2026: 113228. | |
| Cas No. | 500271-63-6 | SDF | |
| Formula | C23H24FN5O | M.Wt | 405.47 |
| الذوبان | DMSO : 50 mg/mL (123.31 mM; Need ultrasonic) | Storage | -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.4663 mL | 12.3314 mL | 24.6627 mL |
| 5 mM | 493.3 μL | 2.4663 mL | 4.9325 mL |
| 10 mM | 246.6 μL | 1.2331 mL | 2.4663 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)